Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings in Brief: Safeskin

This article was originally published in The Gray Sheet

Executive Summary

Safeskin: Files registration statement with SEC for a secondary offering of 3.2 mil. shares by insider shareholders. Neil Braverman, Safeskin's co-chairman and director, will sell 2 mil. shares; 1 mil. shares are slated to be sold by chairman emeritus Irving Jaffe; and 200,000 shares are offered by Chairman, President and CEO Richard Jaffe. Following the offering, Braverman, Jaffe and Jaffe will continue to own approximately 19.4% of Safeskin's voting stock, the company says. Smith Barney and Merrill Lynch are underwriters. Separately, Safeskin adopts a shareholder rights plan that would go into effect if a person or group acquired beneficial ownership of 15% of Safeskin outstanding stock...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT007298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel